These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26715915)

  • 1. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.
    Thomas AL; Coarfa C; Qian J; Wilkerson JJ; Rajapakshe K; Krett NL; Gunaratne PH; Rosen ST
    Nucl Recept Signal; 2015; 13():e006. PubMed ID: 26715915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells.
    Palagani A; Op de Beeck K; Naulaerts S; Diddens J; Sekhar Chirumamilla C; Van Camp G; Laukens K; Heyninck K; Gerlo S; Mestdagh P; Vandesompele J; Berghe WV
    PLoS One; 2014; 9(12):e113842. PubMed ID: 25474406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma.
    Grugan KD; Ma C; Singhal S; Krett NL; Rosen ST
    J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):244-54. PubMed ID: 18499442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.
    Tessel MA; Benham AL; Krett NL; Rosen ST; Gunaratne PH
    Horm Cancer; 2011 Jun; 2(3):182-9. PubMed ID: 21761344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression.
    Medh RD; Saeed MF; Johnson BH; Thompson EB
    Cancer Res; 1998 Aug; 58(16):3684-93. PubMed ID: 9721879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.
    Huang X; Yang M; Jin J
    Leuk Lymphoma; 2012 Jun; 53(6):1188-95. PubMed ID: 22260163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
    Clarisse D; Prekovic S; Vlummens P; Staessens E; Van Wesemael K; Thommis J; Fijalkowska D; Acke G; Zwart W; Beck IM; Offner F; De Bosscher K
    Cell Mol Life Sci; 2023 Aug; 80(9):249. PubMed ID: 37578563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.
    Moalli PA; Pillay S; Weiner D; Leikin R; Rosen ST
    Blood; 1992 Jan; 79(1):213-22. PubMed ID: 1728309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).
    Sánchez-Vega B; Gandhi V
    Br J Haematol; 2009 Mar; 144(6):856-64. PubMed ID: 19133980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.
    Kervoëlen C; Ménoret E; Gomez-Bougie P; Bataille R; Godon C; Marionneau-Lambot S; Moreau P; Pellat-Deceunynck C; Amiot M
    Oncotarget; 2015 Sep; 6(29):26922-34. PubMed ID: 26323097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [P38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
    He L; Li D; Hou KZ; Liu YP
    Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia.
    Ploner C; Schmidt S; Presul E; Renner K; Schröcksnadel K; Rainer J; Riml S; Kofler R
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):153-60. PubMed ID: 15860257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis and modeling of glucocorticoid-controlled gene expression.
    Chen DW; Lynch JT; Demonacos C; Krstic-Demonacos M; Schwartz JM
    Pharmacogenomics; 2010 Nov; 11(11):1545-60. PubMed ID: 21121775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA.
    Gomi M; Moriwaki K; Katagiri S; Kurata Y; Thompson EB
    Cancer Res; 1990 Mar; 50(6):1873-8. PubMed ID: 2106390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells.
    Sánchez-Vega B; Krett N; Rosen ST; Gandhi V
    Mol Cancer Ther; 2006 Dec; 5(12):3062-70. PubMed ID: 17172408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies.
    Clarisse D; Van Wesemael K; Tavernier J; Offner F; Beck IM; De Bosscher K
    PLoS One; 2018; 13(5):e0197000. PubMed ID: 29738549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to glucocorticoid-induced apoptosis in human T-cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression.
    Geley S; Hartmann BL; Hala M; Strasser-Wozak EM; Kapelari K; Kofler R
    Cancer Res; 1996 Nov; 56(21):5033-8. PubMed ID: 8895760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.